Drug Trial Radar · NCT06277245
A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis.
Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
356
Actual
Start
Feb 6, 2024
Primary completion
Apr 18, 2025
Study completion Jan 12, 2026
Sponsor
- Lead sponsor
- Lynk Pharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind study comparing LNK01001 to placebo in participants with moderately to severely atopic dermatitis who were candidates for systemic therapy (ie, patients with a history of inadequate response to topical treatments, those who were using a systemic treatment, or those for whom topical treatments are otherwise medically inadvisable). The objective of this study is to evaluate the efficacy and safety of LNK01001 in adult patients with moderate to severe AD who are candidates for systemic therapy.
Conditions
- Atopic Dermatitis
Interventions
LNK01001Drug
Capsule; Oral
PlaceboDrug
Capsule; Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Eczema Area and Severity Index (EASI-75) at Week 16Time frame: Baseline and Week 16
- Investigator's Global Assessment (IGA) score of 0/1 at Week 16Time frame: Baseline and Week 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dermatological Hospital of Southern Medical University
Guangzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.